Edition:
India

Bio-Techne Corp (TECH.OQ)

TECH.OQ on NASDAQ Stock Exchange Global Select Market

132.43USD
22 Nov 2017
Change (% chg)

$0.31 (+0.23%)
Prev Close
$132.12
Open
$132.17
Day's High
$132.81
Day's Low
$131.51
Volume
56,217
Avg. Vol
63,715
52-wk High
$132.81
52-wk Low
$95.68

Summary

Name Age Since Current Position

Robert Baumgartner

61 2012 Independent Chairman of the Board

Charles Kummeth

57 2014 President, Chief Executive Officer, Director

James Hippel

45 2014 Chief Financial Officer, Senior Vice President

Brenda Furlow

58 2014 Senior Vice President, General Counsel, Secretary

David Eansor

54 2015 Senior Vice President - Biotechnology

Robert Gavin

48 2014 Senior Vice President-Protein Platforms

Kevin Gould

52 2016 Senior Vice President-Clinical Controls

Joseph Keegan

62 2017 Director

Alpna Seth

54 2017 Director

Charles Dinarello

74 2005 Independent Director

John Higgins

47 2009 Independent Director

Roeland Nusse

66 2010 Independent Director

Randolph Steer

67 1990 Independent Director

David Clair

2016 IR Contact Officer

Biographies

Name Description

Robert Baumgartner

Mr. Robert V. Baumgartner CPA is Independent Chairman of the Board of Bio-Techne Corporation. He received a bachelor’s degree in business administration from the University of Notre Dame. Mr. Baumgartner has served as Executive Chairman, Director of the Center for Diagnostic Imaging, Inc., an operator of diagnostic imaging centers, since 2001. Until August 2015, Mr. Baumgartner also served as Chief Executive Officer of that company. Prior to 2001, he held numerous executive positions, including as Chief Executive Officer and Director of American Coating International, President and Chief Executive Officer of First Solar and President of the Apogee Glass Group. He began his professional career at KPMG LLC, an international accounting firm. Mr. Baumgartner currently serves on the boards of Carestream Health, Inc. and Invenshure LLC.

Charles Kummeth

Mr. Charles R. Kummeth is President, Chief Executive Officer, Director of Bio-Techne Corporation. Prior to joining the Company, he served as President of Mass Spectrometry and Chromatography at Thermo Fisher Scientific Inc. from September 2011. He was President of that company’s Laboratory Consumables Division from 2009 to September 2011. Prior to joining Thermo Fisher, Mr. Kummeth served in various roles at 3M Corporation, most recently as a Vice President of the company’s Medical Division from 2006 to 2008. Mr. Kummeth also serves on the board of Sparton Corp, an electromechanical device company.

James Hippel

Mr. James T. Hippel is a Senior Vice President, Chief Financial Officer of the Company. Prior to joining the Company, Mr. Hippel served as Senior Vice President and Chief Financial Officer for Mirion Technologies, Inc., a $300 million global company that provides radiation detection and identification products. Prior to Mirion, Mr. Hippel served as Vice President, Finance at Thermo Fisher Scientific, Inc., leading finance operations for its Mass Spectrometry & Chromatography division and its Laboratory Consumables division. In addition, Mr. Hippel’s experience includes nine years of progressive financial leadership at Honeywell International, within its Aerospace Segment. Mr. Hippel started his career with KPMG LLP.

Brenda Furlow

Ms. Brenda S. Furlow J.D. is a Senior Vice President, General Counsel, Secretary of the Company. Most recently, Ms. Furlow was an associate with Alphatech Counsel, SC and served as general counsel to emerging growth technology companies. Ms. Furlow was General Counsel for TomoTherapy, Inc., a global, publicly traded company that manufactured and sold radiation therapy equipment from 2007 to 2011. From 1998 to 2007, Ms. Furlow served as General Counsel for Promega Corporation, a global life sciences company. In addition, Ms. Furlow’s experience includes five years in various positions with a credit union trade association. Ms. Furlow began her legal career as an associate with a Chicago-based law firm.

David Eansor

Mr. David Eansor is a Senior Vice President - Biotechnology of the Company. Prior to that, Mr. Eansor was Senior Vice President, Novus Biologicals, since the Company completed its acquisition of Novus on July 2, 2014. From January 2013 until the date of the acquisition, Mr. Eansor was the Senior Vice President of Corporate Development of Novus Biologicals. Prior to joining Novus, Mr. Eansor was the President of the Bioscience Division of Thermo Fisher Scientific. Mr. Eansor was promoted to Division President in early 2010 after 5 years as President of Thermo Fisher’s Life Science Research business.

Robert Gavin

Mr. Robert Gavin is a Senior Vice President-Protein Platforms of the company. Mr. Gavin had previously been Vice President of Product Development at ProteinSimple, which was acquired by the Company in July, 2014. Prior to joining ProteinSimple in 2008, Mr. Gavin served as Director of Engineering at MDS Analytical Technologies (previously Molecular Devices, Inc.). Prior to Molecular Devices, Mr. Gavin managed a team of engineers at Affymax Research Institute.

Kevin Gould

Mr. Kevin S. Gould is Senior Vice President-Clinical Controls of the Company. Prior to that, Mr. Gould was President and CEO of Cliniqa prior to its acquisition by Bio-Techne in July 2015. Prior to Cliniqa, Mr. Gould held senior level positions in other diagnostic product business, including Vice President, SeraCare BBI Diagnostics business unit of SeraCare Life Sciences, Inc.; and Vice President, Sales & Marketing for Medical Analysis Systems Inc., now part of Thermo Fisher Scientific Inc.

Joseph Keegan

Dr. Joseph D. Keegan, Ph.D., is Director of the Company. Keegan has held leadership positions in several life science tools and diagnostics companies, including Molecular Devices, Becton Dickinson and Leica, and most recently as President and CEO of ForteBio, Inc. until its sale to Pall Corporation in 2012. Since 2012, Kegan has been a director and advisor for a number of life science tools companies, including publicly-traded Interpace Diagnostics and a several private company boards.

Alpna Seth

Dr. Alpna Seth is a Director of the Company. Seth is Chief Operating Officer of Vir Biotechnology, Inc. Seth joined Vir in July of this year as its COO. Vir integrates diverse innovations in science, technology, and medicine to transform the care of people with serious infectious diseases. Prior to joining Vir, Seth held a variety of executive roles at Biogen, including most recently as Senior Vice President and Global head of the Biosimilars business for Biogen with headquarters in Switzerland.

Charles Dinarello

Dr. Charles A. Dinarello M.D. is Independent Director of Bio-Techne Corporation. Dr. Dinarello received his medical degree from Yale University and his clinical training at the Massachusetts General Hospital, and, among other positions, has been employed by the National Institutes of Health. Since 1996, Dr. Dinarello has been Professor of Medicine and Immunology at the University of Colorado School of Medicine in Aurora, Colorado, and he is currently also Professor of Experimental Medicine at Radboud University in the Netherlands. Previously, he was Professor of Medicine and Pediatrics at Tufts University School of Medicine and a staff physician at the New England Medical Center Hospital in Boston. From March 2009 to February 2011, Dr. Dinarello served as an acting CEO of Omni Bio Pharmaceutical, Inc. In 1998, Dr. Dinarello was elected to the United States National Academy of Sciences, and in 2010, he was made a foreign member of the Royal Netherlands Academy of Sciences. Dr. Dinarello is considered one of the founding fathers of cytokine biology, and regularly speaks at symposia around the world. For his research in the field, Dr. Dinarello has won numerous awards: the Novartis Prize in Clinical Immunology, the Paul Ehrlich Prize, the Bonsfils-Staton Award, the Royal Swedish Academy of Sciences Crafoord Prize in Polyarthritis, the Albany Medical Center Prize in Medical and Biomedical Research (the largest U.S. prize in medicine), the Squibb Award, the Ernst Jung Prize of Medicine, the Gold Medal of Heilmeyer Society for International Medicine, the Chirone Prize, the Carol Nachman Prize, the Sheikh Hamdan bin Rashdid al Maktoum Award, the Beering Prize, and the Bonazinga Award. In November 2012, Mr. Dinarello received the Lifetime Achievement Award of the Eicosanoid Foundation for his pioneering studies in the role of lipids in cytokine-mediated inflammation, and in June of 2014, he received the Drexel Prize in Immunology.

John Higgins

Mr. John L. Higgins is Independent Director of Bio-Techne Corporation. He graduated Magna Cum Laude with a bachelor’s degree from Colgate University. Mr. Higgins has been President and Chief Executive Officer of Ligand Pharmaceuticals, Inc. since January 2007 and has been a member of Ligand’s Board of Directors since March 2007. From 1997 until joining Ligand, Mr. Higgins was with Connetics Corporation, a specialty pharmaceutical company, as its Chief Financial Officer, and also served as an Executive Vice President, Finance and Administration and Corporate Development at Connetics from January 2002 until its acquisition by Stiefel Laboratories, Inc. in December 2006. Mr. Higgins was previously a member of the executive management team and a director at BioCryst Pharmaceuticals, Inc., a biopharmaceutical company. Before joining BioCryst in 1994, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins also serves as Chairman of CoMentis, Inc., a biopharmaceutical company, and has served as a director of numerous public and private companies.

Roeland Nusse

Dr. Roeland Nusse Ph.D. is Independent Director of Bio-Techne Corporation. Dr. Nusse earned a bachelor’s degree in biology from the University of Amsterdam and a doctorate in molecular biology from the Netherlands Cancer Institute in 1980. He did his postdoctoral fellowship at the University of California, San Francisco. Dr. Nusse has served as Chairman of the Department of Developmental Biology at Stanford University since 2007. Dr. Nusse has been a professor or associate professor in the Department of Developmental Biology at Stanford University and an investigator at the Howard Hughes Medical Institute since 1990. He has also been the chair of the Department of Developmental Biology at Stanford since 2007. Dr. Nusse was previously at the Netherlands Cancer Institute (Amsterdam, The Netherlands) as a staff scientist and ultimately head of the Department of Molecular Biology. Dr. Nusse was elected to the United States National Academy of Sciences in April 2010. Dr. Nusse was previously named a member of the European Molecular Biology Organization in 1988, a member of the Royal Dutch Academy of Sciences in 1997 and a member of the American Academy of Arts and Sciences in 2001.

Randolph Steer

Dr. Randolph C. Steer M.D. Ph.D. is Independent Director of Bio-Techne Corporation. Dr. Steer receive his undergraduate degree in physiology and Ph.D. in pathobiology from the University of Minnesota and his medical degree from the Mayo Medical School. Dr. Steer is currently an independent biotechnology consultant. He served as President and Chief Operating Officer of Capstone Therapeutics Corp. from April 2006 to October 2011. Dr. Steer was elected to the Mayo Clinic Board of Trustees in November 2011. In the past five years, Dr. Steer also served as a director of Vital Therapies, Inc. From 1989 to 2006 Dr. Steer was a consultant to the pharmaceutical and biotechnology industries, where he advised companies in business development, medical marketing and regulatory and clinical affairs. His prior experience includes service as Associate Director of Medical Affairs at Marion Laboratories and as Medical Director at Ciba Consumer Pharmaceuticals.

David Clair

Basic Compensation

Name Fiscal Year Total

Robert Baumgartner

281,312

Charles Kummeth

9,076,890

James Hippel

2,226,770

Brenda Furlow

754,004

David Eansor

1,347,200

Robert Gavin

1,215,240

Kevin Gould

1,102,110

Joseph Keegan

--

Alpna Seth

--

Charles Dinarello

245,312

John Higgins

262,979

Roeland Nusse

241,312

Randolph Steer

256,979

David Clair

--
As Of  30 Jun 2017